Abcellera Biologics vs Fortress Biotech
Abcellera Biologics is the larger business, with $75.1m of revenue in fiscal 2025 against $63.3m for Fortress Biotech (1.2 times as much). Abcellera Biologics grew faster (160.6% against 9.7%). Fortress Biotech kept more of each dollar of sales as profit: a net margin of 10.8% against -194.9%.
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | Fortress BiotechFBIO, 2025 |
|---|---|---|
| Revenue | $75.1m | $63.3m |
| Revenue growth | 160.6% | 9.7% |
| Net income | −$146m | $6.8m |
| Operating margin | -289.0% | — |
| Net margin | -194.9% | 10.8% |
| Return on equity | -14.5% | 18.8% |
| Free cash flow | −$174m | −$65.8m |
| Cash | $129m | $79.4m |
| Total debt | $0 | $54.5m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | 0.8% |
| Share buybacks | — | — |
| Employees | 562 | 78 |
| Market value | $3.71bn | $64.5m |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 20 (Weak) |
| Insider trades, 12 months | 9 buys, 0 sales | 0 buys, 0 sales |